[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"atheroma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:atheroma":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,43],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100612380","identification-of-asymptomatic-patients-at-very-high-cardiovascular-risk-contribution-of-a-strategy-based-on-carotid-and-coronary-explorations-compared-to-simple-risk-calculation-using-the-european-score-2-algorithm-idea-cvr-100612380",false,"NCT07252830","Identification of Asymptomatic Patients at Very High Cardiovascular Risk: Contribution of a Strategy Based on Carotid and Coronary Explorations, Compared to Simple Risk Calculation Using the European \"SCORE 2\" Algorithm. (IDEA-CVR)","Identification of Asymptomatic Patients at Very High Cardiovascular Risk: Contribution of a Strategy Based on Carotid and Coronary Explorations, Compared to Simple Risk Calculation Using the European \"SCORE 2\" Algorithm.","IDEA-CVR","Inclusion Criteria:\n\n* Age \\> 40 years and \\\u003C 80 years referred to general cardiology consultation\n* LDL-C level \\> 1.6 g\u002FL, or LDL-C level \\> 1.3 g\u002FL with at least one associated major cardiovascular (CV) risk factor (RCF) (smoking, hypertension, diabetes).\n* Coronary artery reserve assessment and EDTSA performed in a day hospital\n\nExclusion Criteria:\n\n* Known or suspected carotid atherosclerotic disease\n* Significant ischemic heart disease known or suspected at the time of the initial consultation\n* Protected adult patient (patient under guardianship, curatorship, or other legal protection, deprived of liberty by judicial or administrative decision)\n* Opposition expressed by the patient to the use of their health data.\n* Patient may have limited understanding of the information sheet","ALL","40 Years","80 Years",{"count":21,"type":22},1000,"ESTIMATED","OBSERVATIONAL","To prevent myocardial infarction ( MI), coronary atheroma development by LDL-cholesterol deposition in the arterial wall is the basis. Since atheromatous plaques develop slowly before becoming symptomatic, their early detection in asymptomatic patients and the implementation of an effective strategy to prevent their progression constitute the most promising primary prevention strategy. In younger subjects, the main modifiable pro-atheromatous factors are smoking and an excessively high LDL-C level, partly genetically predetermined, but also favored by a diet too rich in saturated fats and a lack of physical activity. In the French national MI registry, the average age of patients is 62 years (Arch Cardiovasc Dis 2021 Oct;114(10):647-655). Half of MIs therefore occur at working age due to rupture of atheromatous plaques, which had developed during the months\u002Fyears preceding the acute event.\n\nAccording to the latest recommendations of the European Society of Cardiology (ESC) on CV prevention published in August 2021, the visualization of coronary or carotid atheromatous plaques justifies considering the patient as having atherosclerotic cardiovascular disease (ASCVD), and automatically places them in the \"very high CV risk\" category, with an LDL-cholesterol target of \\\u003C0.55 g\u002FL. However, these recommendations do not clearly define the criteria justifying the use of imaging in asymptomatic patients.\n\nIn current practice, CV risk stratification for asymptomatic patients with no prior CV disease is currently based on risk calculation using the European \"SCORE 2\" algorithm, available online. It allows the calculation of the absolute risk in % of occurrence of a fatal or non-fatal CV event (myocardial infarction, stroke) over 10 years.\n\nThe main objective of this study is to describe patients reclassified as \"very high CV risk\" following the detection of atheroma plaques formed in relation to their risk level estimated by SCORE2.",[26,27,28,29],"Myocardial Infarction","Atheroma","Cholesterol","Cardiovascular (CV) Risk","RECRUITING","2025-11-19",{"date":33,"type":34},"2025-11-28","ACTUAL",{"date":36,"type":34},"2021-09-12",{"date":38,"type":22},"2026-01-20",{"name":40,"class":41},"Elsan","OTHER",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":17,"minAge":50,"maxAge":19,"enrollmentInfo":51,"targetDuration":4,"studyType":53,"phases":54,"briefSummary":56,"conditions":57,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":42},"100545830","prospective-multicenter-cohort-study-to-validate-four-groups-of-biomarkers-for-assessing-lung-cancer-risk-among-patients-with-atheromatous-cardiovascular-disease-in-a-screening-pathway-100545830","NCT06387017","Prospective Multicenter Cohort Study to Validate Four Groups of Biomarkers for Assessing Lung Cancer Risk Among Patients With Atheromatous Cardiovascular Disease in a Screening Pathway","BIOCEPTION","Inclusion Criteria:\n\n* 1- All PREVALUNG or PREVALUNG ETOILE participants\n* 2- Active or former smokers who have smoked daily for at least 10 years and have either atheromatous disease (coronary, lower limb, supra-aortic trunk, aortic, visceral or upper limb arteries) or a moderate or high coronary calcium score\\*, \\*\\*.\n\nInclusion criteria:\n\n* Age 45- 75 years and\n* Medical follow-up for smoking-related atheromatous pathology and\n* daily smoking for at least 10 years prior to disease (for smoking, there are no quantitative criteria or withdrawal times)\n\n  * visual coronary calcium score quantified by a radiologist on a chest CT scan.\n\n    3- Individuals at risk of lung cancer without atheromatous disease or moderate or high calcium score being managed for a tobacco-related disease (chronic bronchitis or non-progressive cancer \\> 5 years) or with eligibility criteria for lung cancer screening (inclusion criteria in the NLST or NELSON studies or American recommendations)\\*\\*.\n\nInclusion criteria :\n\n* Age 45- 75 and\n* Medical follow-up for a smoking-related pathology:\n* chronic obstructive pulmonary disease \u002F emphysema, or\n* history of non-progressive cancer \\> 5 years, including ENT, lung, breast, cervix, excreto-urinary tract, bladder, esophagus, stomach, pancreas, liver, kidney, chronic myeloid leukemia.\n\nand\n\n\\- daily smoking for at least 10 years prior to the disease (for smoking, there are no quantitative criteria or withdrawal periods).\n\nOr\n\nInclusion criteria in NLST :\n\n* Age 55 - 74\n* Cumulative smoking ≥ 30 pack-years\n* active or weaned for less than 15 years Or\n\nNELSON inclusion criteria :\n\n* Age 50-75\n* Smoking :\n* \\> 15 cigarettes \u002FD for more than 25 years or\n* \\> 10 cigarettes \u002FD for more than 30 years\n* active smoking or cessation \\\u003C 10 years Or\n\nAmerican recommendations :\n\n* Age 50 - 80\n* Smoking ≥20 PA\n\nExclusion Criteria:\n\n* cancer history \\\u003C 5 years (except carcinoma in situ of the uterine cervix, basal cell carcinoma of the skin, non-invasive urothelial carcinoma treated for curative purposes without CT lung surveillance, prostate cancer with unmeasurable PSA)\n* symptoms of lung cancer (involuntary weight loss \\> 7 kg in 1 year, hemoptysis)\n* known history of pulmonary nodule requiring specialized follow-up\n* history of pulmonary fibrosis or pulmonary hypertension\n* active pulmonary parenchymal infection\n* severe cardiac or respiratory insufficiency (rest dyspnea)\n* performance status (WHO) 2, 3 or 4\n* patient not affiliated to the social security system (beneficiary or beneficiary's beneficiary)\n* patient deprived of liberty\n* patients under guardianship or trusteeship\n* pregnant or breast-feeding women","45 Years",{"count":52,"type":22},750,"INTERVENTIONAL",[55],"NA","Interventional study with minimal risks and constraints, with evaluation of the incidence of lung cancers by low-dose thoracic CT scan without injection of contrast medium, of the immunological, inflammatory and metabolic blood profile and of the microbiota; systematic proposal of smoking cessation for active smokers or assistance in maintaining cessation.",[58,27,59,60],"Smoking-related Pathology","Non-progressive Cancer > 5 Years","Lung Cancer","2024-04-24",{"date":63,"type":34},"2024-04-26",{"date":65,"type":34},"2024-04-02",{"date":67,"type":22},"2029-07",{"name":69,"class":41},"Assistance Publique Hopitaux De Marseille"]